Custom Pro5® MHC Class I PentamersProImmune has over 10 years experience making custom MHC multimers specific to customers’ requirements. Our technical expertise and experience in making thousands of MHC-peptide complexes means that we are able to provide custom reagents efficiently and with a high rate of success. Our customers can expect the same consistency and reliability from our custom reagents as our regularly ordered catalog Pentamers. In addition, all labeled custom Pro5® Pentamers come with a six month performance guarantee, and unlabeled custom Pentamers have a twelve month guarantee. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
You can now opt for faster dispatch by choosing the Rapid Synthesis option: Rapid Custom Pro5® MHC Class I Pentamer ServiceWhen time is critical in your project, you can now choose custom Pentamers for dispatch in only 12 working days. This service, which includes peptide synthesis, is designed to beat the timescales of any external source of MHC multimers, such as tetramers - whether commercial or core facility. Your rapid synthesis custom Pentamer is made to the same uncompromising quality standards as our standard delivery-time custom Pentamers and is supplied with the same guarantee, 6 months for a labeled Pentamer, 12 months for an unlabeled Pentamer. Rapid Pentamer Service Specification(1) The rapid synthesis service is limited to a maximum of 4 custom MHC
Class I Pentamers per order and to the 50 test pack size. Download Rapid Pentamer Service Specification Ordering Custom Pro5® Pentamers and related products
Case Study: Epitope Discovery in Prostate CancerThe Use of H-2Db / HCIRNKSVI (PSA 65-73) Custom Pro5® MHC Class I Pentamer in the Characterization of an Immunodominant CTL Epitope of PSA in MicePavlenko, M. et al. (2005) Identification of an immunodominant H-2Db-restricted CTL epitope of human PSA. Prostate 64: 50-59 [PubMedID: 15651071]. Prostate cancer is a serious condition affecting 1 in 6 men. Prostate specific antigen (PSA) expression is increased in prostate cancer and so is exploited not only for diagnosing and monitoring prostate cancer, but also as a potential target for immunotherapy. By working with Custom Pro5® Pentamers from ProImmune, Pavlenko et al. have identified and validated an immunodominant cytotoxic T lymphocyte (CTL) epitope of PSA in C57BL/6 mice. A combined bioinformatics approach using the SYFPEITHI website (www.syfpeithi.com), and biochemical MHC-peptide stabilization assays was used to define the candidate epitope (H-2Db / HCIRNKSVI) and a custom Pro5® Pentamer was synthesized. PSA-specific CTLs were induced by immunizing mice with a plasmid expressing PSA (pVax-PSA). By using both functional assays, intracellular cytokine staining and detection of PSA-specific CD8+ T cells with Pro5® Pentamer staining, the authors were able to demonstrate correlating frequencies of both IFN-g positive and Pentamer positive T cells following in vitro stimulation with the specific peptide. The authors conclude that “Pentamer technology enables detection of T cell receptor specific T-cell populations and allows, in combination with functional assays, the discrimination between anergy and tolerance induction during effector responses. H-2Db Pentamers assembled with this peptide are an efficient tool for the monitoring of PSA-specific CTL responses after DNA vaccination”.
Figure: 12 days after immunization as described, the splenocytes were restimulated for 5 days in vitro with 1nM of psa65-73 (HCIRNKSVI) peptide (A). The PSA-specific T cells were detected by staining with the H-2Db/HCIRNKSVI Pentamer (B). The splenocytes were stimulated for 5hr with 10nM of the psa65-73 or GP33 (negative control) peptides and stained with the antibodies against CD8 and IFN-gamma.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

